The role of progestin subdermal implant in the management of adenomyosis: a systematic review

G Chene, Chene G, G. Chêne, Baffet H, H Baffet, Hortense Baffet, E. Cerruto, Nohuz E, E. Nohuz, Aubert Agostini, Agostini A, A. Agostini
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2024 · vol. 29(2) , pp. 61–68 · doi:10.1080/13625187.2024.2314298 · PMID:38426337 · W4392354471
review OA: closed CC0 ⤵ 1 in-corpus citation
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This systematic review of five studies found the progestin subdermal implant significantly reduced pelvic pain and dysmenorrhea, and increased hemoglobin levels in women with adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-17 · read from full text ⓘ

This systematic review evaluated the effectiveness of the etonogestrel-releasing progestin subdermal implant for managing adenomyosis by analyzing five prospective observational studies involving 152 participants. The authors found that the device significantly reduced pelvic pain and dysmenorrhea while increasing hemoglobin levels, with benefits sustained over long-term follow-up periods up to 36 months. Although bleeding pattern changes were the most common adverse event, they were generally tolerable; however, the authors explicitly note that randomized controlled trials with larger cohorts are needed to confirm these findings. This paper is centrally about adenomyosis — specifically assessing the clinical efficacy of hormonal contraception in reducing symptoms associated with this condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PURPOSE: The long-acting reversible contraception progestin subdermal implant (ENG implant) may be effective to improve endometriosis-related symptoms. Since adenomyosis is a histopathological form of endometriosis, we aimed to evaluate the effectiveness of ENG implant in adenomyosis management. MATERIALS AND METHODS: Electronic search in Medline, Scopus, Embase databases and Google Scholar using combinations of the following keywords: Progestin; subdermal implant; Implanon; Nexplanon; Adenomyosis; Endometriosis. RESULTS: Out of 889 articles in the initial database, 5 prospective observational studies were eligible for inclusion in our literature review. Our review involving 152 participants found a significant reduction in pelvic pain and dysmenorrhoea (baseline median VAS score ranged from 10 to 7.62 before implantation vs VAS score ranged from 1.81 to 0.1 after implantation) as well as an increase in the levels of haemoglobin after implantation of the device (from 86 g/L to 129 g/L after implantation). Moreover, the improvement may be sustained throughout the long-term follow-up visits (until 36 months). The most common adverse events were changes in bleeding patterns which were tolerable in most cases. CONCLUSION: ENG implant may be a relevant and promising medical option in the management of adenomyosis. Nevertheless, randomised controlled trials and prospective studies with larger cohorts are needed to confirm the potential role of ENG implant in the management of adenomyosis.
Full text 2,304 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Purpose The long-acting reversible contraception progestin subdermal implant (ENG implant) may be effective to improve endometriosis-related symptoms. Since adenomyosis is a histopathological form of endometriosis, we aimed to evaluate the effectiveness of ENG implant in adenomyosis management

Materials and methods

Electronic search in Medline, Scopus, Embase databases and Google Scholar using combinations of the following keywords: Progestin; subdermal implant; Implanon; Nexplanon; Adenomyosis; Endometriosis.

Results

Out of 889 articles in the initial database, 5 prospective observational studies were eligible for inclusion in our literature review. Our review involving 152 participants found a significant reduction in pelvic pain and dysmenorrhoea (baseline median VAS score ranged from 10 to 7.62 before implantation vs VAS score ranged from 1.81 to 0.1 after implantation) as well as an increase in the levels of haemoglobin after implantation of the device (from 86 g/L to 129 g/L after implantation). Moreover, the improvement may be sustained throughout the long-term follow-up visits (until 36 months). The most common adverse events were changes in bleeding patterns which were tolerable in most cases.

Conclusion

ENG implant may be a relevant and promising medical option in the management of adenomyosis. Nevertheless, randomised controlled trials and prospective studies with larger cohorts are needed to confirm the potential role of ENG implant in the management of adenomyosis SHORT CONDENSATION The etonogestrel-releasing subdermal contraceptive implant may be a relevant medical option in the management of adenomyosis. 摘要 目的 长效可逆孕激素皮下埋植剂(ENG皮下埋植剂)可有效改善子宫内膜异位症相关症状。由于子宫腺肌病是子宫内膜异位症的一种组织病理学形式, 我们的目的是评价ENG皮下埋植剂在子宫腺肌病治疗中的有效性。 材料和方法 检索Medline、Scopus、Embase数据库和Google Scholar, 以下关键词进行组合: 孕激素；皮下埋植剂；依伴侬；依托孕烯植入剂；子宫腺肌病；子宫内膜异位症。 结果 在数据库中初始检索到889篇文章, 有5篇前瞻性观察性研究符合文献纳入标准。对152名参与者的综述发现, 盆腔疼痛和痛经显著减少(植入前中位VAS评分为10到7.62, 植入后中位VAS评分为1.81到0.1), 以及植入后血红蛋白水平上升(从植入前的86g/L上升到129g/L)。此外, 这种改善可能长期持续至整个随访期间(直到36个月)。最常见的不良事件是出血模式的改变, 这在大多数情况下是可以耐受的。 结论 ENG皮下埋植剂可能是治疗子宫腺肌病的一种有前景的医疗选择。然而, 需要随机对照试验和更大队列的前瞻性研究来证实ENG皮下埋植剂在治疗子宫腺肌病中的潜在作用。

Acknowledgements

The authors thank Dea Špiljarić for her advice in medical manuscript editing. Data availability Data are available upon reasonable request.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

dysmenorrheachronic_pelvic_painendometriosisadenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (1)

SciLite annotations

chemicals 2
progestin progestin

Source provenance

europepmc
last seen: 2026-09-21T06:08:07.822426+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-09-22T06:09:42.487365+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
unpaywall
last seen: 2026-09-22T06:12:16.469521+00:00
License: CC0 · commercial use OK